InMed Pharmaceuticals (INM) Receivables - Net (2021 - 2025)
InMed Pharmaceuticals' Receivables - Net history spans 5 years, with the latest figure at $182967.0 for Q4 2025.
- For Q4 2025, Receivables - Net fell 30.32% year-over-year to $182967.0; the TTM value through Dec 2025 reached $182967.0, down 30.32%, while the annual FY2025 figure was $465104.0, 31.82% up from the prior year.
- Receivables - Net reached $182967.0 in Q4 2025 per INM's latest filing, down from $343469.0 in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $465104.0 in Q2 2025 to a low of $14842.0 in Q3 2021.
- Average Receivables - Net over 5 years is $171682.0, with a median of $125973.0 recorded in 2022.
- Peak YoY movement for Receivables - Net: soared 428.4% in 2024, then plummeted 30.32% in 2025.
- A 5-year view of Receivables - Net shows it stood at $50304.0 in 2021, then surged by 62.31% to $81647.0 in 2022, then decreased by 18.21% to $66775.0 in 2023, then skyrocketed by 293.21% to $262569.0 in 2024, then plummeted by 30.32% to $182967.0 in 2025.
- Per Business Quant, the three most recent readings for INM's Receivables - Net are $182967.0 (Q4 2025), $343469.0 (Q3 2025), and $465104.0 (Q2 2025).